Insight Molecular Diagnostics Stock Pattern Recognition Two Crows
| IMDX Stock | 4.90 0.01 0.20% |
| Symbol |
Recognition |
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. Two Crows is a 3-day pattern that warns about a possible future trend reversal for Insight Molecular.
Insight Molecular Technical Analysis Modules
Most technical analysis of Insight Molecular help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Insight from various momentum indicators to cycle indicators. When you analyze Insight charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
The stock is undergoing the symbol change. Insight Molecular symbol was changed from OCX on 18th of June 2025.Insight Molecular is publicly traded on the NASDAQ Exchange in United States. A high-level view of Insight Molecular emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 196.27. Insight Molecular has a market cap of 150.59 M, ROE of -236.03%.
Methodology
Unless otherwise specified, financial data for Insight Molecular Diagnostics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Insight (USA Stocks:IMDX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA) as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Insight Molecular Diagnostics is covered by 4 analysts. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Stifel, Barclays, Morgan Stanley, Wells Fargo Securities, Evercore ISI, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardLearn to be your own money manager
Tracking Insight Molecular inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
Insight Molecular pair trading
Pair trading with Insight Molecular can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Insight Molecular Pair Trading
Insight Molecular Diagnostics Pair Trading Analysis
Correlation analysis helps investors find suitable substitutes for Insight Molecular during tax-loss harvesting periods. Selling Insight Molecular Diagnostics at a loss and immediately repurchasing it would violate IRS wash-sale rules, so a correlated replacement asset is required to maintain portfolio.
Measuring the statistical correlation of Insight Molecular against other instruments helps investors understand portfolio diversification. A correlation near zero implies that Insight Molecular provides genuine diversification benefits, while high positive correlations suggest redundant exposures.
Correlation analysis and pair trading evaluation for Insight Molecular can be used to frame hedging context. The context can be applied within sectors, industries, or broader universes.More Resources for Insight Stock Analysis
A structured review of Insight Molecular often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame Insight Molecular Diagnostics Stock in context:Insight Molecular has a market cap of 150.59 M, operating margin of -29.5%, ROE of -236.03%. Use Risk vs Return Analysis to explore allocation context. This includes a position in Insight Molecular Diagnostics across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. Analysis related to Insight Molecular should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Earnings Share -3.21 | Revenue Per Share | Quarterly Revenue Growth 1.261 | Return On Assets | Return On Equity |
The market value of Insight Molecular is measured differently than book value, which reflects Insight accounting equity. Insight Molecular's market capitalization is 150.59 M. With a P/B ratio of 196.27, the market values Insight Molecular well above its book equity. Enterprise value stands at 137.89 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Insight Molecular's intrinsic value and market price are different measures derived from different inputs. For Insight Molecular, key inputs include a P/B ratio of 196.27, ROE of -236.03%, and revenue of 1.88 M. Trading price represents the transaction level agreed by market participants.